Valion Bio, Inc. Related Party Transaction, Expenses from Transactions with Related Party
Valion Bio, Inc. (VBIO) reported Related Party Transaction, Expenses from Transactions with Related Party of $18.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty · last filed 2023-03-31
- Valion Bio, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2022-12-31 was $0.00.
- Valion Bio, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2022-09-30 was $5.00K.
- Valion Bio, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2022-06-30 was $10.00K.
- Valion Bio, Inc. related party transaction, expenses from transactions with related party for the quarter ending 2022-03-31 was $3.00K.
- Valion Bio, Inc. related party transaction, expenses from transactions with related party for fiscal 2022 was $18.00K, a 500.00% increase from fiscal 2021.
- Valion Bio, Inc. related party transaction, expenses from transactions with related party for fiscal 2021 was $3.00K.
| Period end | Related Party Transaction, Expenses from Transactions with Related Party 3 month | Related Party Transaction, Expenses from Transactions with Related Party 6 month | Related Party Transaction, Expenses from Transactions with Related Party 9 month | Related Party Transaction, Expenses from Transactions with Related Party 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $5.00K derived: sum of 2 quarters · filed 2023-03-31 | $15.00K derived: sum of 3 quarters · filed 2023-03-31 | $18.00K 10-K · filed 2023-03-31 |
| 2022-09-30 | $5.00K 10-Q · filed 2022-11-14 | $15.00K derived: sum of 2 quarters · filed 2022-11-14 | $18.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $10.00K 10-Q · filed 2022-08-15 | $13.00K 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $3.00K derived: 10-K 12 month − 3 quarters · filed 2023-03-31 | |||
| 2021-12-31 | $3.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |